Sanjay Kaul, MD
Cardiology · Los Angeles, CANPI 1790713071
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $888,150 of the $1,119,151 with a category attached, or 79.4%. 52 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 25.8% of the total. Reporting peaked in 2019 at $256,602 and has fallen 75.0% since, to $64,109 in 2025. Among cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $3432.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$289K
- Bayer$69K
- Novo Nordisk$64K
- GSK$62K
- Boehringer Ingelheim$49K
- Boehringer Ingelheim (phil.) Inc.$43K
- plus $543K from 46 others
Across 1 payment — averaging $11,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$12K
What the payments were for
- Consulting fees$888,15079%
- Speaking & faculty fees$127,79011%
- Travel & lodging$96,8099%
- Food & beverage$6,3731%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$396,476
- Kerendia$53,029
- GLYXAMBI$33,535
- TRADJENTA$33,535
- Rinvoq$26,400
- CARVYKTI$17,000
- Norditropin$16,593
- Leqembi$16,000
- Non-Covered$15,415
- AFX2 Bifurcated Endograft System$14,400
- IMBRUVICA$14,400
- Beleodaq$14,400
- ENTRESTO$11,088
- AURYXIA$9,800
- PASCAL$9,100
- EYLEA HD$8,800
- FARXIGA$3,200
- SYNJARDY$2,800
- HTX-011$1,300
- REXULTI$1,160
How this compares
$1,119,151 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $87,873 |
| JardianceEmpagliflozin | 50 | $47,959 |
| EntrestoSacubitril/Valsartan | 31 | $37,236 |
| MounjaroTirzepatide | 20 | $20,847 |
| Repatha SureclickEvolocumab | 22 | $19,732 |
| VascepaIcosapent Ethyl | 34 | $16,567 |
| TradjentaLinagliptin | 16 | $12,893 |
| Praluent PenAlirocumab | 24 | $12,002 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 13 | $9,526 |
| Diclofenac Epolamine | 13 | $8,081 |
| XareltoRivaroxaban | 11 | $7,861 |
| Dexlansoprazole DrDexlansoprazole | 18 | $2,812 |
| Ezetimibe | 120 | $2,580 |
| Metoprolol Succinate | 100 | $2,210 |
| Hydrocortisone Butyrate | 13 | $2,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $87,87376 claims |
| Boehringer IngelheimJardiance, Tradjenta | $48,969 | $60,85266 claims |
| NovartisEntresto | $27,567 | $37,23631 claims |
| Lilly USA, LLCMounjaro | $84 | $20,84720 claims |
| AbbVieSynthroid | $40,746 | $63316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.
Other cardiology in Los Angeles
- Jamshid MaddahiLos Angeles$59K
- Hooman MadyoonLos Angeles$24K
- Andrew KimLos Angeles$5K
- Shawn ShahLos Angeles$3K
- Mark UrmanLos Angeles$1K
- Hiram PalmerLos Angeles$979
- Rene PackardLos Angeles$774
- Michael WongLos Angeles$510
- Norman LeporBeverly Hills$1.9M
- Ramtin AgahMountain View$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.